443 related articles for article (PubMed ID: 8076383)
21. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
22. [Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study].
Emin Erbaycu A; Gunduz A; Batum O; Zeren Ucar Z; Tuksavul F; Zeki Guclu S
Arch Bronconeumol; 2010 Jul; 46(7):364-9. PubMed ID: 20537457
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of tumor markers in the management of small cell lung cancer].
Ariyoshi Y
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):959-65. PubMed ID: 2839115
[TBL] [Abstract][Full Text] [Related]
24. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
25. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
26. [Serum neuron-specific enolase (NSE) in patients with small cell lung cancer--comparison with carcinoembryonic antigen (CEA)].
Kawahara M; Furuse K; Arai R; Tsuruta M; Kodama N; Hayashi S; Kiyota M; Kubota K; Mori T; Yamamoto S
Gan To Kagaku Ryoho; 1987 Jan; 14(1):146-51. PubMed ID: 3026253
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers and IL-2R in lung cancer.
Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL
Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891
[TBL] [Abstract][Full Text] [Related]
28. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE].
Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H
Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic value of combined detection of TPS, NSE and CEA in lung cancer].
Zheng H; He BF; Luo RC
Di Yi Jun Yi Da Xue Xue Bao; 2003 Feb; 23(2):165-6. PubMed ID: 12581971
[TBL] [Abstract][Full Text] [Related]
30. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
31. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
Yang J; Li R; Li A
Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
[TBL] [Abstract][Full Text] [Related]
32. [Role of the cut-off value of serum neuron-specific enolase in differentiating small cell lung cancer from non-small cell lung cancer].
Wei T; Luo RC; Zuo Q; Zhang JY; Miao JX; Lu HF
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):858-9. PubMed ID: 16793621
[TBL] [Abstract][Full Text] [Related]
33. Multiple tumour markers for diagnosis, management and follow-up of potentially resectable lung cancer.
Ratto GB; Mereu C; Rovida S
Panminerva Med; 1993 Dec; 35(4):186-92. PubMed ID: 8202329
[TBL] [Abstract][Full Text] [Related]
34. Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer.
Nitta T; Fukuoka M; Masuda N; Kusunoki Y; Matsui K; Kudoh S; Hirashima T; Yana T; Ito K; Takada M
Jpn J Clin Oncol; 1995 Oct; 25(5):179-83. PubMed ID: 7474404
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
36. Neuron-specific enolase (NSE) serum level in non small cell lung cancer--can it be an indicator of tumour chemosensitivity?
Zych J; Sakowicz A; Radzikowska E; Załeska J; Rowińska-Zakrzewska E
Rocz Akad Med Bialymst; 1997; 42 Suppl 1():173-8. PubMed ID: 9337535
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
[TBL] [Abstract][Full Text] [Related]
38. Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.
Ebert W; Muley T; Trainer C; Dienemann H; Drings P
Anticancer Res; 2002; 22(2B):1083-9. PubMed ID: 12168905
[TBL] [Abstract][Full Text] [Related]
39. Carcinoembryonic antigen, neuron-specific enolase and creatine kinase-BB as tumor markers for carcinoma of the lung.
Nikliński J; Furman M; Palynyczko Z; Laudański J; Bułatowicz J
Neoplasma; 1991; 38(6):645-51. PubMed ID: 1766488
[TBL] [Abstract][Full Text] [Related]
40. Multiple sequential biomarkers in monitoring patients with carcinoma of the lung.
Aroney RS; Dermody WC; Aldenderfer P; Parsons P; McNitt K; Marangos PJ; Whitacre MY; Ruddon RW; Wiernik PH; Aisner J
Cancer Treat Rep; 1984 Jun; 68(6):859-66. PubMed ID: 6329508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]